(RPRX) Royalty Pharma - Ratings and Ratios
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: GB00BMVP7Y09
Royalties, Rare Disease, Cancer, Neuroscience, Diabetes
Dividends
| Dividend Yield | 2.20% |
| Yield on Cost 5y | 2.32% |
| Yield CAGR 5y | 29.36% |
| Payout Consistency | 100.0% |
| Payout Ratio | 19.5% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 23.1% |
| Value at Risk 5%th | 36.1% |
| Relative Tail Risk | -5.06% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.68 |
| Alpha | 47.46 |
| CAGR/Max DD | -0.01 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.216 |
| Beta | 0.288 |
| Beta Downside | 0.196 |
| Drawdowns 3y | |
|---|---|
| Max DD | 41.68% |
| Mean DD | 25.43% |
| Median DD | 28.71% |
Description: RPRX Royalty Pharma October 16, 2025
Royalty Pharma plc (NASDAQ:RPRX) purchases biopharmaceutical royalty streams and provides financing to U.S. drug developers, building a portfolio that currently includes royalties on roughly 35 marketed medicines and 14 late-stage candidates across therapeutic areas such as rare diseases, oncology, neuroscience, infectious disease, hematology, and diabetes.
As of the latest filing (Q2 2024), the company reported a market-capitalization of about $2.6 billion, an enterprise-value-to-royalty-cash-flow multiple near 8.5×, and a weighted-average royalty yield of ~ 7 % on its assets, indicating a relatively high-yield, low-beta exposure to the biotech sector. The balance sheet remains strong, with > $1.5 billion of cash and liquid investments, supporting ongoing acquisition capacity.
Key sector drivers include accelerating FDA approvals for specialty therapies, rising prevalence of chronic and rare conditions, and sustained venture-capital inflows into biotech R&D, all of which expand the pool of royalty-generating assets. For a deeper, data-driven view of Royalty Pharma’s valuation dynamics, you may find ValueRay’s analyst dashboard worth a look.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (765.0m TTM) > 0 and > 6% of Revenue (6% = 141.0m TTM) |
| FCFTA 0.12 (>2.0%) and ΔFCFTA -3.08pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 56.12% (prev 27.65%; Δ 28.48pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.12 (>3.0%) and CFO 2.41b > Net Income 765.0m (YES >=105%, WARN >=100%) |
| Net Debt (8.03b) to EBITDA (1.58b) ratio: 5.07 <= 3.0 (WARN <= 3.5) |
| Current Ratio 3.48 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (559.6m) change vs 12m ago -5.63% (target <= -2.0% for YES) |
| Gross Margin 78.88% (prev 60.56%; Δ 18.32pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 12.57% (prev 12.56%; Δ 0.01pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 5.83 (EBITDA TTM 1.58b / Interest Expense TTM 279.3m) >= 6 (WARN >= 3) |
Altman Z'' 1.67
| (A) 0.07 = (Total Current Assets 1.85b - Total Current Liabilities 530.8m) / Total Assets 19.35b |
| (B) 0.12 = Retained Earnings (Balance) 2.30b / Total Assets 19.35b |
| (C) 0.09 = EBIT TTM 1.63b / Avg Total Assets 18.69b |
| (D) 0.24 = Book Value of Equity 2.30b / Total Liabilities 9.73b |
| Total Rating: 1.67 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 58.02
| 1. Piotroski 5.0pt |
| 2. FCF Yield 7.84% |
| 3. FCF Margin data missing |
| 4. Debt/Equity 1.40 |
| 5. Debt/Ebitda 5.07 |
| 6. ROIC - WACC (= 1.98)% |
| 7. RoE 11.59% |
| 8. Rev. Trend 14.13% |
| 9. EPS Trend 10.09% |
What is the price of RPRX shares?
As of December 01, 2025, the stock is trading at USD 40.02 with a total of 1,621,044 shares traded.
Over the past week, the price has changed by +0.68%, over one month by +6.61%, over three months by +11.26% and over the past year by +55.23%.
Over the past week, the price has changed by +0.68%, over one month by +6.61%, over three months by +11.26% and over the past year by +55.23%.
Is RPRX a buy, sell or hold?
Royalty Pharma has received a consensus analysts rating of 4.25.
Therefore, it is recommended to buy RPRX.
- Strong Buy: 4
- Buy: 2
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the RPRX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 46 | 14.9% |
| Analysts Target Price | 46 | 14.9% |
| ValueRay Target Price | 48 | 19.9% |
RPRX Fundamental Data Overview November 25, 2025
Market Cap USD = 22.70b (22.70b USD * 1.0 USD.USD)
P/E Trailing = 22.24
P/E Forward = 11.534
P/S = 9.659
P/B = 2.5931
P/EG = 1.7139
Beta = 0.466
Revenue TTM = 2.35b USD
EBIT TTM = 1.63b USD
EBITDA TTM = 1.58b USD
Long Term Debt = 8.57b USD (from longTermDebt, last quarter)
Short Term Debt = 383.1m USD (from shortTermDebt, last quarter)
Debt = 8.97b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 8.03b USD (from netDebt column, last quarter)
Enterprise Value = 30.71b USD (22.70b + Debt 8.97b - CCE 955.0m)
Interest Coverage Ratio = 5.83 (Ebit TTM 1.63b / Interest Expense TTM 279.3m)
FCF Yield = 7.84% (FCF TTM 2.41b / Enterprise Value 30.71b)
FCF Margin = 102.4% (FCF TTM 2.41b / Revenue TTM 2.35b)
Net Margin = 32.55% (Net Income TTM 765.0m / Revenue TTM 2.35b)
Gross Margin = 78.88% ((Revenue TTM 2.35b - Cost of Revenue TTM 496.4m) / Revenue TTM)
Gross Margin QoQ = 99.79% (prev 64.76%)
Tobins Q-Ratio = 1.59 (Enterprise Value 30.71b / Total Assets 19.35b)
Interest Expense / Debt = 0.89% (Interest Expense 79.6m / Debt 8.97b)
Taxrate = 35.12% (156.0m / 444.2m)
NOPAT = 1.06b (EBIT 1.63b * (1 - 35.12%))
Current Ratio = 3.48 (Total Current Assets 1.85b / Total Current Liabilities 530.8m)
Debt / Equity = 1.40 (Debt 8.97b / totalStockholderEquity, last quarter 6.41b)
Debt / EBITDA = 5.07 (Net Debt 8.03b / EBITDA 1.58b)
Debt / FCF = 3.34 (Net Debt 8.03b / FCF TTM 2.41b)
Total Stockholder Equity = 6.60b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.95% (Net Income 765.0m / Total Assets 19.35b)
RoE = 11.59% (Net Income TTM 765.0m / Total Stockholder Equity 6.60b)
RoCE = 10.74% (EBIT 1.63b / Capital Employed (Equity 6.60b + L.T.Debt 8.57b))
RoIC = 7.22% (NOPAT 1.06b / Invested Capital 14.64b)
WACC = 5.24% (E(22.70b)/V(31.66b) * Re(7.08%) + D(8.97b)/V(31.66b) * Rd(0.89%) * (1-Tc(0.35)))
Discount Rate = 7.08% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 33.33 | Cagr: 11.94%
[DCF Debug] Terminal Value 78.58% ; FCFE base≈2.56b ; Y1≈2.61b ; Y5≈2.89b
Fair Price DCF = 119.1 (DCF Value 50.88b / Shares Outstanding 427.2m; 5y FCF grow 1.81% → 3.0% )
EPS Correlation: 10.09 | EPS CAGR: 10.67% | SUE: 0.74 | # QB: 0
Revenue Correlation: 14.13 | Revenue CAGR: 1.52% | SUE: -1.00 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.16 | Chg30d=-0.070 | Revisions Net=-1 | Analysts=1
EPS current Year (2025-12-31): EPS=4.63 | Chg30d=+0.189 | Revisions Net=+5 | Growth EPS=+12.3% | Growth Revenue=+13.2%
EPS next Year (2026-12-31): EPS=5.05 | Chg30d=+0.023 | Revisions Net=+1 | Growth EPS=+9.1% | Growth Revenue=+2.8%
P/E Trailing = 22.24
P/E Forward = 11.534
P/S = 9.659
P/B = 2.5931
P/EG = 1.7139
Beta = 0.466
Revenue TTM = 2.35b USD
EBIT TTM = 1.63b USD
EBITDA TTM = 1.58b USD
Long Term Debt = 8.57b USD (from longTermDebt, last quarter)
Short Term Debt = 383.1m USD (from shortTermDebt, last quarter)
Debt = 8.97b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 8.03b USD (from netDebt column, last quarter)
Enterprise Value = 30.71b USD (22.70b + Debt 8.97b - CCE 955.0m)
Interest Coverage Ratio = 5.83 (Ebit TTM 1.63b / Interest Expense TTM 279.3m)
FCF Yield = 7.84% (FCF TTM 2.41b / Enterprise Value 30.71b)
FCF Margin = 102.4% (FCF TTM 2.41b / Revenue TTM 2.35b)
Net Margin = 32.55% (Net Income TTM 765.0m / Revenue TTM 2.35b)
Gross Margin = 78.88% ((Revenue TTM 2.35b - Cost of Revenue TTM 496.4m) / Revenue TTM)
Gross Margin QoQ = 99.79% (prev 64.76%)
Tobins Q-Ratio = 1.59 (Enterprise Value 30.71b / Total Assets 19.35b)
Interest Expense / Debt = 0.89% (Interest Expense 79.6m / Debt 8.97b)
Taxrate = 35.12% (156.0m / 444.2m)
NOPAT = 1.06b (EBIT 1.63b * (1 - 35.12%))
Current Ratio = 3.48 (Total Current Assets 1.85b / Total Current Liabilities 530.8m)
Debt / Equity = 1.40 (Debt 8.97b / totalStockholderEquity, last quarter 6.41b)
Debt / EBITDA = 5.07 (Net Debt 8.03b / EBITDA 1.58b)
Debt / FCF = 3.34 (Net Debt 8.03b / FCF TTM 2.41b)
Total Stockholder Equity = 6.60b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.95% (Net Income 765.0m / Total Assets 19.35b)
RoE = 11.59% (Net Income TTM 765.0m / Total Stockholder Equity 6.60b)
RoCE = 10.74% (EBIT 1.63b / Capital Employed (Equity 6.60b + L.T.Debt 8.57b))
RoIC = 7.22% (NOPAT 1.06b / Invested Capital 14.64b)
WACC = 5.24% (E(22.70b)/V(31.66b) * Re(7.08%) + D(8.97b)/V(31.66b) * Rd(0.89%) * (1-Tc(0.35)))
Discount Rate = 7.08% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 33.33 | Cagr: 11.94%
[DCF Debug] Terminal Value 78.58% ; FCFE base≈2.56b ; Y1≈2.61b ; Y5≈2.89b
Fair Price DCF = 119.1 (DCF Value 50.88b / Shares Outstanding 427.2m; 5y FCF grow 1.81% → 3.0% )
EPS Correlation: 10.09 | EPS CAGR: 10.67% | SUE: 0.74 | # QB: 0
Revenue Correlation: 14.13 | Revenue CAGR: 1.52% | SUE: -1.00 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.16 | Chg30d=-0.070 | Revisions Net=-1 | Analysts=1
EPS current Year (2025-12-31): EPS=4.63 | Chg30d=+0.189 | Revisions Net=+5 | Growth EPS=+12.3% | Growth Revenue=+13.2%
EPS next Year (2026-12-31): EPS=5.05 | Chg30d=+0.023 | Revisions Net=+1 | Growth EPS=+9.1% | Growth Revenue=+2.8%
Additional Sources for RPRX Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle